Videos

Hepatotoxicity with KRASG12C Inhibitors in NSCLC

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

Optimal Approach for PD-L1 >50%

Dr Narjust Florez discusses the hepatoxicity associated with KRAS G12C inhibitors, noting both adagrasib and sotorasib pose liver damage risks, but real-world data suggests adagrasib may have a lower risk; she emphases the importance of considering other causes of hepatoxicity before attributing it solely to these therapies.

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD

Treatment for Borderline Resectable Patients With NSCLC

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD

Long-Term Outcomes of Sotorasib Efficacy in Patients With KRASG12C Mutated NSCLC

Discussion on the treatment for borderline resectable patients with NSCLC.

Tucatinib/T-DM1 Yield ‘Exciting’ Results in HER2+ Metastatic Breast Cancer

CodeBreaK 100 compares the safety and efficacy of pembrolizumab combined with adagrasib or sotorasib in treating KRAS G12C NSCLC, noting sotorasib has a longer presence and familiarity in clinical use.

Adding trastuzumab emtansine to tucatinib appears to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer, says Sara Hurvitz, MD, FACP.

Sara A. Hurvitz, MD

PERSEUS: Daratumumab plus VRd in Newly Diagnosed Multiple Myeloma Patients

Adding trastuzumab emtansine to tucatinib appears to significantly improve progression-free survival in patients with metastatic HER2-positive breast cancer, says Sara Hurvitz, MD, FACP.

Luciano Costa, MD, PhD;Philippe Moreau, MD;Larry Anderson, MD, PhD, FACP

Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Luciano Costa, MD, reviews recent data from the PERSEUS trial investigating the combination of daratumumab, bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients.

A panel of 4 experts on multiple myeloma seated at a long table

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

Emerging Research in CAR T-Cell Therapy in R/R Multiple Myeloma

An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.

Kathleen Dorritie, MD;Joseph Franz, MD;Dhaval Mehta, MD;Christina Waters, PA-C

Case Presentation: Clinical Decision Making in a R/R MM patient

A panel of multiple myeloma specialists discuss emerging data and ongoing research that are informing treating paradigms for patients with multiple myeloma.

Caitlin Costello, MD

2-Minute Drill: The Biggest Surprise From the 2023 ASH Annual Meeting

Caitlin Costello, MD, discusses her insights and considerations when choosing the next line of therapy in a patient with relapsed/refractory multiple myeloma.

Joshua Richter, MD

Available Treatment Options for Patients With Stage-III Resectable NSCLC

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss highlights of the conference in a game show–style production.

Gregory Gan, MD, PhD;Alykhan Nagji, MD;Krishna Reddy, MD, PhD;Vinay Raja, MD

Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC

Alykhan Nagji, MD, provides a brief overview of the landscape surrounding the treatment of patients with stage-III resectable NSCLC.

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Christina S. Wu, MB, BCh, MD;Kristen K. Ciombor, MD, MSCI;Stacy A. Cohen, MD

Future Perspectives and Unmet Needs in HER2+ mCRC Treatment

The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Christina S. Wu, MB, BCh, MD;Kristen K. Ciombor, MD, MSCI;Stacy A. Cohen, MD

Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma

Drs Ciombor and Ahn discuss emerging HER2-targeted therapies in colorectal cancer, including antibody-drug conjugates and novel antibodies.

$Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma$

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.

Cesar Rodriguez, MD, an expert on multiple myeloma

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP

Evolving Front-line Treatment Options for CLL

Comprehensive insights on the clinical management of adverse events from talquetamab seen in patients with multiple myeloma, including cytokine release syndrome and infections.

Sameer A. Parikh, MD;Sikander Ailawadhi, MD;Mazie Tsang, MD, MAS, MS;Amber Koehler, PA-C, MS

December 18th 2023

In this Cancer Network Around the Practice program, Mazie Tsang, MD offers an overview of the current landscape surrounding frontline therapy in CLL.

Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.

Pembrolizumab/Chemo Improves Responses in dMMR/pMMR Endometrial Cancer

Ramez Eskander, MD

December 18th 2023

Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.

A panel of 4 experts on breast cancer seated at a long table

Advancements in Treatment Strategies for HER2+ Metastatic Breast Cancer: Insights from Experts at the Duke Cancer Center

Carey K. Anders, MD;Heather Moore, CPP, PharmD;Rani Bansal, MD;Susan Dent, MD

December 17th 2023

In this Cancer Network Around the Practice program, Susan Dent, MD discusses the case of a 66-year-old patient with grade 3 triple-positive breast cancer who presents with multiple liver and bone metastases after front-line treatment with trastuzumab and letrozole.

$Treatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.$

Data Support Liso-cel as an ‘Important’ Therapy in Relapsed/Refractory CLL

Tatyana Feldman, MD

Recent Data in Relapsed/Refractory Acute Myeloid Leukemia

Treatment with lisocabtagene maraleucel in the TRANSCEND CLL 004 study raises no new safety concerns in patients with relapsed/refractory chronic lymphocytic leukemia, says Tatyana Feldman, MD.

Ghayas C. Issa, MD

Overview of Relapsed or Refractory Multiple Myeloma (RRMM)

A medical oncologist reviews clinical trial data for revumenib and ziftomenib for patients with relapsed/refractory acute myeloid leukemia.

$Overview of Relapsed or Refractory Multiple Myeloma (RRMM)$

Sagar Lonial, MD, FACP;Ellen Marin, PA-C

The Role of KMT2Ar/NPM1 and Menin in Relapsed/Refractory AML

Sagar Lonial, MD, provides an overview of the currently available treatment options in relapsed/refractory multiple myeloma.

Ghayas C. Issa, MD

KRYSTAL-7: Efficacy and Safety of Adagrasib with Pembrolizumab in Patients With Advanced KRASG12C Mutated NSCLC

Ghayas C. Issa, MD, discusses the pathway between KMT2A rearrangements/NPM1 and menin in relation to leukemia cells and how these genetic abnormalities impact prognosis.

KRYSTAL-1: Follow-Up Data on Adagrasib Monotherapy in Patients with Advanced/Metastatic KRASG12C Mutated NSCLC

KRYSTAL-7 is a study exploring the efficacy of adding adagrasib to first-line pembrolizumab in patient with NSCLC with varying PD-L1 expression levels, showing promising response rates and progression-free survival, but also adverse events like hepatotoxicity.

PFS With Ibrutinib Combo is ‘Promising’ in Chronic Lymphocytic Leukemia

Dr Narjust Florez discusses the KRYSTAL-1 trial, focusing on the effectiveness and side effects of adagrasib in treating patients with NSCLC and KRASG12C mutations, and noting their impact on progression-free and overall survival.

Ibrutinib plus venetoclax appears to be effective across the overall chronic lymphocytic leukemia population in the CAPTIVATE study, although progression-free survival is shorter for those with TP53 mutations.

Paolo Ghia, MD, PhD

KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Ibrutinib plus venetoclax appears to be effective across the overall chronic lymphocytic leukemia population in the CAPTIVATE study, although progression-free survival is shorter for those with TP53 mutations.

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS

Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Deborah Doroshow, MD;Neel Chudgar, MD;Vamsidhar Velcheti, MD;Daniel R. Gomez, MD;Jamie E Chaft, MD;Fred R. Hirsch, MD, PhD;Mark G. Kris, MD

Exploring Novel Treatment Options in Patients With RRMM

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Carolina D. Schinke, MD;Joselle Cook, M.B.B.S;Luciano Costa, MD, PhD;Binod Dhakal, MD, MS